BIONTECH SE - AMERICAN DEPOSITARY SHARES

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

19 Nov 2021 08:25:27 By Nasdaq GlobeNewswire

BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma

19 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update

09 Nov 2021 06:45:00 By Nasdaq GlobeNewswire

BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting

01 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years

29 Oct 2021 17:45:00 By Nasdaq GlobeNewswire

Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs

28 Oct 2021 06:58:34 By Nasdaq GlobeNewswire

BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

27 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years

26 Oct 2021 18:19:08 By Nasdaq GlobeNewswire

BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022

26 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

21 Oct 2021 06:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union

04 Oct 2021 12:10:00 By Nasdaq GlobeNewswire

BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting

01 Oct 2021 08:12:36 By Nasdaq GlobeNewswire

BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

01 Oct 2021 02:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries

22 Sep 2021 06:02:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

20 Sep 2021 06:45:00 By Nasdaq GlobeNewswire

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

18 Sep 2021 03:40:00 By Nasdaq GlobeNewswire

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

27 Aug 2021 07:15:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America

26 Aug 2021 06:46:32 By Nasdaq GlobeNewswire

Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

25 Aug 2021 12:10:00 By Nasdaq GlobeNewswire

Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older

23 Aug 2021 11:55:00 By Nasdaq GlobeNewswire